Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T96837
|
|||||
| Target Name |
Immunoglobulin gamma-1 heavy NIE (NIE)
|
|||||
| Synonyms |
Immunoglobulin gamma-1 heavy chain NIE
Click to Show/Hide
|
|||||
| Gene Name |
NIE
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | Diabetes mellitus [ICD-11: 5A10] | |||||
| 2 | Rheumatoid arthritis [ICD-11: FA20] | |||||
| Function |
Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170).
Click to Show/Hide
|
|||||
| UniProt ID | ||||||
| Sequence |
QVQLVQSGGGVVQPGRSLRLSCAASGFTFSRYTIHWVRQAPGKGLEWVAVMSYNGNNKHY
ADSVNGRFTISRNDSKNTLYLNMNSLRPEDTAVYYCARIRDTAMFFAHWGQGTLVTVSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | MORAb-022 | Drug Info | Phase 1 | Autoimmune diabetes | [2] | |
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: L-ornithine | Ligand Info | |||||
| Structure Description | Crystal Structure of a Broadly Neutralizing Anti-HIV-1 Antibody in Complex with a Peptide Mimotope | PDB:1N0X | ||||
| Method | X-ray diffraction | Resolution | 1.80 Å | Mutation | No | [3] |
| PDB Sequence |
QVQLVQSGAE
10 VKKPGASVKV20 SCQASGYRFS30 NFVIHWVRQA40 PGQRFEWMGW50 INPYNGNKEF 59 SAKFQDRVTF69 TADTSANTAY79 MELRSLRSAD86 TAVYYCARVG96 PYSWDDSPQD 100F NYYMDVWGKG106 TTVIVSSAST116 KGPSVFPLAP126 SSTAALGCLV144 KDYFPEPVTV 154 SWNSGALTSG169 VHTFPAVLQS180 SGLYSLSSVV191 TVPSSSLGTQ203 TYICNVNHKP 214 SNTKVDKKVE226 PK
|
|||||
|
|
||||||
| Ligand Name: Glutarate | Ligand Info | |||||
| Structure Description | X-ray crystal structure of covalent-bonded complex of Fc and peptide | PDB:6IQH | ||||
| Method | X-ray diffraction | Resolution | 3.00 Å | Mutation | No | [4] |
| PDB Sequence |
GPSVFLFPPK
246 PKDTLMISRT256 PEVTCVVVDV266 SHEDPEVKFN276 WYVDGVEVHN286 AKTKPREEQY 296 NSTYRVVSVL306 TVLHQDWLNG316 KEYKCKVSNK326 ALPAPIEKTI336 SKAKGQPREP 346 QVYTLPPSRD356 ELTKNQVSLT366 CLVKGFYPSD376 IAVEWESNGQ386 PENNYKTTPP 396 VLDSDGSFFL406 YSKLTVDKSR416 WQQGNVFSCS426 VMHEALHNHY436 TQKSLSL |
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Similarity Proteins
|
|
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 2 | ClinicalTrials.gov (NCT01357759) Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects. U.S. National Institutes of Health. | |||||
| REF 3 | Crystal Structure of a Broadly Neutralizing Anti-HIV-1 Antibody in Complex with a Peptide Mimotope | |||||
| REF 4 | Site-Specific Chemical Conjugation of Antibodies by Using Affinity Peptide for the Development of Therapeutic Antibody Format. Bioconjug Chem. 2019 Mar 20;30(3):698-702. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.